CTOs on the Move


 
Genexa is the world`s first and only clean medicine company and was recognized in 2022 by Fast Company as the no. 1 Most Innovative Company in Wellness. We were founded in 2016 by two dads who believed medicine should only have the active ingredients you need, and not the artificial fillers you don`t. It`s medicine made clean, because that`s what people deserve. Our headquarters is located in Atlanta, where we strive to put people over everything
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.genexa.com
  • 1510 Ellsworth Industrial Boulevard NW Building Two, Suite 10
    Atlanta, GA USA 30318
  • Phone: 855.436.3921

Executives

Name Title Contact Details

Similar Companies

Exela Pharma Sciences

Exela Pharma Sciences is a Lenoir, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vision Innovation Partners

Vision Innovation Partners unites the mid-Atlantic’s premier ophthalmology practices and surgery centers through good people, expert leadership, the sharing of best practices and the backing of a leading middle-market private equity firm.

Turbaremanufacturing

Turbare Manufacturing is a company that specializes in the sterile production of intravenous medications, FDA drug shortage preparations, and critical medication preparations to help fulfill the critical needs in the pharmaceutical supply chain.

Monte Rosa Therapeutics

Small molecule protein degraders are set to reshape the way by which diseases will be treated. Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020. Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.